Close Menu

Precision Oncology News: Breaking News

The Phase III Keynote-775 study has shown that the combination improves overall and progression-free survival compared to chemotherapy.

In early 2021, the company will begin human studies of a drug that it believes will be the first Hippo-YAP targeting agent to enter the clinic.

The grant, awarded by the Eurostars program, will support the European companies in their goal of advancing their mRNA-based kidney cancer vaccine.

Oncocyte will receive upfront cash payments after transferring and installing DetermaRx, in addition to certain tests after it achieves inclusion in the US Comprehensive Cancer Network.

The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer.

The study is evaluating the drug in previously treated NSCLC patients with alterations in EGFR, ALK, ROS1, NTRK, BRAF, MET, or RET.

The collaboration, through which Hummingbird will have access to Tempus' TIME Trial Network, is focused on advancing the HER3-targeted agent, HMBD-001.

The Roche subsidiary will take over development of RLY-1971 and study it in combination with other drugs, such as its KRAS G12C inhibitor GDC-6036.

The decision is based on data from the Phase II HER2CLIMB trial, which evaluated Tukysa in combination with Herceptin and capecitabine.

CHMP issued a positive recommendation for Daiichi Sankyo/AstraZeneca's antibody-drug conjugate following positive results from the DESTINY-Breast01 trial.

Through this partnership, the companies hope to help oncologists make better testing and treatment decisions, as well as improve clinical trial matching.

The European Commission will review CHMP's opinion based on the Keynote-177 data and is expected to issue a final decision in the first quarter of 2021.

The partners are starting by testing patients with colorectal and thyroid cancers using the 648-gene Tempus xT assay, but could expand to other areas in the future.

The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.

The agency recommended the drug based on the results from the Phase III ALTA-1L trial, and after Takeda agreed to offer the drug to NHS England at a discount.

The test, called Immunoscore, is designed to predict the risk of relapse in early-stage colon cancer by measuring host immune responses at tumor sites.

The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.

With clinical sequencing data for almost 400 appendiceal cancer cases, researchers identified somatic differences in individuals diagnosed with the disease before the age of 50.

The FDA has issued a clinical hold on the company's Phase I/II clinical trial of BPX-601 in patients with advanced pancreatic, gastric, and prostate cancer.

Since its founding in 2019, the company has raised $55 million in seed funding from OribMed and 5AM, and in a subsequent Series A financing round.

The organizations said the test will determine and monitor the status of patients using an innovative blood-based mass spectrometry laboratory assay.

The study, slated to begin in the first half of 2021, follows recent discussion with the FDA and promising Phase II data presented at the ASH annual meeting.

Researchers uncovered genetic loci that may influence why childhood cancer survivors of African ancestry are more likely to develop therapy-linked cardiomyopathy.

The FDA has accepted the firm's IND application allowing it to start a dose escalation and expansion study of the drug in the first quarter of 2021.

As part of the deal, Atara will receive $60 million upfront and be eligible for up to $610 million in milestone payments, as well as tiered royalties based on net sales.